This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ARKAY vs. FMC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ARKAY vs. FMC: Which Stock Is the Better Value Option?
Arkema SA (ARKAY) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Arkema SA (ARKAY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Westlake (WLK) & Nexii Partner for Green Building Construction
by Zacks Equity Research
Westlake's (WLK) subsidiary, Westlake Innovations, partners with Nexii to promote the construction of sustainable buildings in order to reduce environmental footprint.
ARKAY vs. FMC: Which Stock Is the Better Value Option?
by Zacks Equity Research
ARKAY vs. FMC: Which Stock Is the Better Value Option?
Here's Why "Trend" Investors Would Love Betting on Arkema SA (ARKAY)
by Zacks Equity Research
Arkema SA (ARKAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Despite Fast-paced Momentum, Arkema SA (ARKAY) Is Still a Bargain Stock
by Zacks Equity Research
Arkema SA (ARKAY) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Linde (LIN) to Increase ASU Production Capacity in Florida
by Zacks Equity Research
Linde (LIN) aims at a 50% increase in production at its Mims site to supply its customers across several markets, which include aerospace, healthcare and food processing.
ARKAY vs. FMC: Which Stock Is the Better Value Option?
by Zacks Equity Research
ARKAY vs. FMC: Which Stock Is the Better Value Option?
What Makes Arkema SA (ARKAY) a Good Fit for "Trend Investing"
by Zacks Equity Research
Arkema SA (ARKAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
ARKAY vs. FMC: Which Stock Is the Better Value Option?
by Zacks Equity Research
ARKAY vs. FMC: Which Stock Is the Better Value Option?
Here's What Could Help Arkema SA (ARKAY) Maintain Its Recent Price Strength
by Zacks Equity Research
Arkema SA (ARKAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Arkema SA (ARKAY) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Arkema SA (ARKAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
ARKAY vs. FMC: Which Stock Is the Better Value Option?
by Zacks Equity Research
ARKAY vs. FMC: Which Stock Is the Better Value Option?
3 Reasons Why Growth Investors Shouldn't Overlook Arkema SA (ARKAY)
by Zacks Equity Research
Arkema SA (ARKAY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Chemicals Market Is Evolving and Growing: 8 Picks
by Sejuti Banerjea
The chemical-diversified industry is poised to grow strongly over the next few years, so this is a great time to get some exposure.
Arkema SA (ARKAY) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Arkema SA (ARKAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ARKAY vs. AIQUY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ARKAY vs. AIQUY: Which Stock Is the Better Value Option?
3 Reasons Why Growth Investors Shouldn't Overlook Arkema SA (ARKAY)
by Zacks Equity Research
Arkema SA (ARKAY) possesses solid growth attributes, which could help it handily outperform the market.
Why Arkema (ARKAY) is Such a Great Value Stock Pick Right Now
by Zacks Equity Research
Arkema (ARKAY) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
ARKAY vs. AKZOY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ARKAY vs. AKZOY: Which Stock Is the Better Value Option?
ARKAY vs. AVNT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ARKAY vs. AVNT: Which Stock Is the Better Value Option?
Arkema SA (ARKAY) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Arkema SA (ARKAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
3 Reasons Growth Investors Will Love Arkema SA (ARKAY)
by Zacks Equity Research
Arkema SA (ARKAY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Chemours (CC) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Chemours (CC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ARKAY or AVNT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ARKAY vs. AVNT: Which Stock Is the Better Value Option?